BR112022019797A2 - Células b modificadas e métodos para uso das mesmas - Google Patents

Células b modificadas e métodos para uso das mesmas

Info

Publication number
BR112022019797A2
BR112022019797A2 BR112022019797A BR112022019797A BR112022019797A2 BR 112022019797 A2 BR112022019797 A2 BR 112022019797A2 BR 112022019797 A BR112022019797 A BR 112022019797A BR 112022019797 A BR112022019797 A BR 112022019797A BR 112022019797 A2 BR112022019797 A2 BR 112022019797A2
Authority
BR
Brazil
Prior art keywords
cell
modified
cells
payload
disease
Prior art date
Application number
BR112022019797A
Other languages
English (en)
Inventor
Boyle Kathleen
Park Hangil
Kothakota Srinivas
Selby Mark
Brennan Thomas
T Williams Lewis
Original Assignee
Walking Fish Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Walking Fish Therapeutics filed Critical Walking Fish Therapeutics
Publication of BR112022019797A2 publication Critical patent/BR112022019797A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4612—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464474—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464495—Prostate specific membrane antigen [PSMA]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

CÉLULAS B MODIFICADAS E MÉTODOS PARA USO DAS MESMAS. A presente invenção se refere a células B modificadas geneticamente e usos das mesmas, por exemplo, para o tratamento de uma variedade de doenças e transtornos, incluindo câncer, doença cardíaca, doença inflamatória, doença de perda muscular, doença neurológica e semelhantes. Em certas modalidades, a invenção se refere a uma célula B modificada isolada (célula CAR-B), com capacidade para expressar um receptor quimérico (receptor CAR-B), em que o dito receptor quimérico compreende (a) um domínio extracelular; (b) um domínio transmembranar; e (c) um domínio citoplasmático que compreende pelo menos um domínio de sinalização. Em várias modalidades, a invenção compreende uma célula B modificada isolada, em que a dita célula B tem capacidade para expressar e secretar uma carga útil, em que a carga útil não é expressada naturalmente em uma célula B ou é expressada em níveis maiores do que é expressada naturalmente em uma célula B. Em várias modalidades, a carga útil é um anticorpo ou fragmento do mesmo.
BR112022019797A 2020-03-31 2021-03-31 Células b modificadas e métodos para uso das mesmas BR112022019797A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063003120P 2020-03-31 2020-03-31
PCT/US2021/025273 WO2021202810A2 (en) 2020-03-31 2021-03-31 Modified b cells and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112022019797A2 true BR112022019797A2 (pt) 2022-12-13

Family

ID=77930050

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019797A BR112022019797A2 (pt) 2020-03-31 2021-03-31 Células b modificadas e métodos para uso das mesmas

Country Status (11)

Country Link
EP (1) EP4127188A2 (pt)
JP (1) JP2023521966A (pt)
KR (1) KR20230006821A (pt)
CN (1) CN115552017A (pt)
AU (1) AU2021249123A1 (pt)
BR (1) BR112022019797A2 (pt)
CA (1) CA3173480A1 (pt)
CL (1) CL2022002667A1 (pt)
IL (1) IL296947A (pt)
MX (1) MX2022012295A (pt)
WO (1) WO2021202810A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019182910A1 (en) * 2018-03-19 2019-09-26 Elwha Llc Compositions and methods for modified b cells expressing reassigned biological agents
US11864683B2 (en) 2020-06-24 2024-01-09 Kalenian Coffee Consulting LLC Methods for producing liquid extracts
CN116426483B (zh) * 2021-12-30 2024-02-23 南京紫珑生物科技有限公司 Cd258蛋白在免疫治疗中的应用
WO2023152752A1 (en) * 2022-02-14 2023-08-17 Ramot At Tel-Aviv University Ltd. Genetic engineering of b cells and uses thereof in antigen-induced therapeutic protein secretion
WO2023172694A1 (en) * 2022-03-09 2023-09-14 Dana-Farber Cancer Institute, Inc. Genetically engineered b cells and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0225279D0 (en) * 2002-10-30 2002-12-11 Celltech R&D Ltd Biological products
ES2536465T3 (es) * 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
ES2828982T3 (es) * 2013-05-14 2021-05-28 Univ Texas Aplicación humana de células t de receptor de antígeno quimérico (car) diseñadas
CA3017678A1 (en) * 2016-04-04 2017-10-12 Eth Zurich Mammalian cell line for protein production and library generation
JP2020517287A (ja) * 2017-04-26 2020-06-18 ユーリカ セラピューティックス， インコーポレイテッド キメラ抗体／ｔ細胞受容体構築物及びその使用

Also Published As

Publication number Publication date
MX2022012295A (es) 2023-03-06
WO2021202810A2 (en) 2021-10-07
CN115552017A (zh) 2022-12-30
IL296947A (en) 2022-12-01
AU2021249123A1 (en) 2022-10-27
KR20230006821A (ko) 2023-01-11
JP2023521966A (ja) 2023-05-26
WO2021202810A3 (en) 2021-11-11
CA3173480A1 (en) 2021-10-07
EP4127188A2 (en) 2023-02-08
CL2022002667A1 (es) 2023-09-22

Similar Documents

Publication Publication Date Title
BR112022019797A2 (pt) Células b modificadas e métodos para uso das mesmas
Burnstock Acupuncture: a novel hypothesis for the involvement of purinergic signalling
BR112017004131A2 (pt) método de produção de uma proteína biológica condicionalmente ativa, proteína biológica condicionalmente ativa, receptor de antígeno quimérico, e, célula citotóxica.
BR112016013187A2 (pt) receptores de antígenos quiméricos de mesotelina humanos e usos dos mesmos
BR112016028755A2 (pt) anticorpo ou fragmento de ligação ao antígeno macromolécula, molécula de ácido nucleico, composição farmacêutica, antígeno, e, métodos para fabricar um anticorpo e para selecionar um anticorpo.
Murugaiyan et al. MicroRNA-21, T helper lineage and autoimmunity
Koo et al. Spontaneous wheel running exercise induces brain recovery via neurotrophin-3 expression following experimental traumatic brain injury in rats
Goldman-Wohl et al. NK cells and pre-eclampsia
BR112022008633A2 (pt) Terapia de células car-t direcionadas a bcma de mieloma múltiplo
BR112022015968A2 (pt) Composições de células t do receptor de antígeno quimérico direcionado a bcma e métodos e usos das mesmas
Zehra et al. Depression and anxiety in women with polycystic ovary syndrome from Pakistan
Giri et al. Effects of sensory stimulation on balance and postural control in diabetic neuropathy: systematic review
McCrum et al. Commentary: Older adults can improve compensatory stepping with repeated postural perturbations
CL2023000602A1 (es) Células b modificadas y métodos de uso de las mismas
Sirota et al. Psychodiagnostics of emotional schemas: the results of transcultural adaptation and assessment of psychometric properties of Russian Version of Leahy Emotional Schema Scale II (LESS II_RUS)
Annesi Relationship of changes in weight, physical activity, and anxiety with blood glucose change in adults with diabetes
Malkova Features visual and auditory gnosis of younger schoolchildren with specific disorders of the development of school skills
Greenwood Trying to keep calm in troubled times: The role of K channels in uterine physiology
Mould John St John Long
BR112023014628A2 (pt) Células t para uso em terapia.
Manchanda et al. Hysteria
Robison et al. Desmin is Critical to the Nuclear Architecture of Cardiomyocytes
Shilpy et al. Role of purva karma in management of cerebral palsy due to brain insult
Michel et al. Age-Dependent Plasticity of Somatosensory Mechanosensation
Tiwari et al. Potentiality of IOT in Resolving Failed Copulation

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: WALKING FISH THERAPEUTICS, INC. (US)